ES2162863T3 - Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. - Google Patents

Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.

Info

Publication number
ES2162863T3
ES2162863T3 ES94916201T ES94916201T ES2162863T3 ES 2162863 T3 ES2162863 T3 ES 2162863T3 ES 94916201 T ES94916201 T ES 94916201T ES 94916201 T ES94916201 T ES 94916201T ES 2162863 T3 ES2162863 T3 ES 2162863T3
Authority
ES
Spain
Prior art keywords
fragment
antibody
functionalized
camelidae
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916201T
Other languages
English (en)
Inventor
Raymond Hamers
Cecile Hamers-Casterman
Serge Victor M Muyldermans
Leon Gerardus J Frenken
Cornelis Theodorus Verrips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Unilever NV
Original Assignee
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27235299&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2162863(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vrije Universiteit Brussel VUB, Universite Libre de Bruxelles ULB, Unilever NV filed Critical Vrije Universiteit Brussel VUB
Application granted granted Critical
Publication of ES2162863T3 publication Critical patent/ES2162863T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PROPORCIONA UNA PROCESO PARA LA PRODUCCION DE UN ANTICUERPO O UN FRAGMENTO O FRAGMENTO (FUNCIONALIZADO) DEL MISMO UTILIZANDO UN HUESPED EUCARIOTICO BAJO TRANSFORMADO QUE CONTIENE UNA SECUENCIA DE ADN EXPRESABLE QUE CODIFICA EL ANTICUERPO O EL FRAGMENTO (FUNCIONALIZADO) DEL MISMO, DONDE EL ANTICUERPO O FRAGMENTO (FUNCIONALIZADO DEL MISMO) SE DERIVA DE UNA CADENA PESADA DE INMUNOGLOBULINA DE CAMELIDAE Y ESTA DESPROVISTO DE CADENAS LIGERAS, DONDE EL HUESPED EUCARIOTICO BAJO ES UN HONGO, QUE PERTENECE PREFERENTEMENTE AL GENERO ASPERGILLUS O TRICHODERMA, O UNA LEVADURA, QUE PERTENECE PREFERENTEMENTE AL GENERO DE LAS LEVADURAS SACCHAROMUYCES, KLUYVEROMYCES, HANSENULA, O PICHIA. EL FRAGMENTO DE CADENA PESADA PUEDE CONTENER AL MENOS EL DOMINIO VARIABLE COMPLETO. UNA REGION DETERMINANTE COMPLEMENTARIA (CDR) DIFERENTE DE LA CDR QUE PERTENECE AL ANTICUERPO NATURAL EX CAMILIDAE PUEDE INJERTARSE EN EL SOPORTE DEL DOMINIO VARIABLE DE LA CADENA PESADA DE INMUNOGLOBINA. LOS ANTICUERPOS CATALIZADORES PUEDEN SER CULTIVADOS EN LA CAMELIDAE FRENTE A LAS MOLECULAS DE ESTADO DE TRANSICION. EL ANTICUERPO FUNCIONALIZADO O FRAGMENTO DEL MISMO PUEDE CONTENER UNA PROTEINA DE FUSION TANTO DE UNA CADENA PESADA DE CAMELIDAE O UN FRAGMENTO DE LA MISMA Y OTRO POLIPEPTIDO, POR EJEMPLO UNA ENZIMA, PREFERENTEMENTE UNA OXIDO-REDUCTASA. TAMBIEN SE PROPORCIONAN NUEVOS PRODUCTOS QUE SE PUEDEN OBTENER MEDIANTE UN PROCESO COMO EL DESCRITO, Y COMPOSICIONES QUE CONTIENEN UN PRODUCTO PRODUCIDO POR UN PROCESO COMO EL DESCRITO, CUYA COMPOSICION PUEDE CONTENER UN NUEVO PRODUCTO COMO EL DESCRITO.
ES94916201T 1993-04-29 1994-04-28 Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae. Expired - Lifetime ES2162863T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93201239 1993-04-29
EP93201454 1993-05-19
EP93202079 1993-07-15

Publications (1)

Publication Number Publication Date
ES2162863T3 true ES2162863T3 (es) 2002-01-16

Family

ID=27235299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916201T Expired - Lifetime ES2162863T3 (es) 1993-04-29 1994-04-28 Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.

Country Status (7)

Country Link
US (2) US6838254B1 (es)
AT (1) ATE204325T1 (es)
AU (1) AU6796094A (es)
DE (1) DE69427974T2 (es)
DK (1) DK0698097T3 (es)
ES (1) ES2162863T3 (es)
WO (1) WO1994025591A1 (es)

Families Citing this family (719)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0739981A1 (en) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US20040248201A1 (en) * 1996-06-27 2004-12-09 Serge Muyldermans Recognition molecules interacting specifically with the active site or cleft of a target molecule
GB9620093D0 (en) * 1996-09-26 1996-11-13 Unilever Plc Photofading inhibitor derivatives and their use in fabric treatment compositions
CA2293304A1 (en) * 1997-06-13 1998-12-17 Unilever Plc Bleaching enzymes
DK1027439T3 (da) 1997-10-27 2010-05-10 Bac Ip Bv Multivalente antigenbindende proteiner
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
EP0954978B1 (en) 1998-03-12 2011-11-30 VHsquared Limited New products comprising inactivated yeasts or moulds provided with active antibodies
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000036094A1 (en) * 1998-12-11 2000-06-22 Unilever N.V. Bleaching enzymes and detergent compositions comprising them
DK1144616T4 (da) * 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
CA2370351A1 (en) * 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
AU6153100A (en) 1999-07-27 2001-02-13 Davis, Paul James Bleaching detergent compositions
EP1118669A3 (en) * 1999-12-17 2001-08-29 Unilever Plc Production of camelid antibodies in plants
ES2251420T3 (es) 1999-12-22 2006-05-01 Unilever N.V. Metodo para tratar tejidos.
ES2295076T3 (es) 1999-12-22 2008-04-16 Unilever N.V. Composiciones detergentes que comprenden agentes ventajosos.
TR200401275T4 (tr) 1999-12-22 2004-07-21 Unilever N.V. Kumaşların muamele edilmesi için yöntem ve bu yöntemde kullanılan aygıt
AU2007901A (en) 1999-12-22 2001-07-03 Unilever Plc Method of delivering a benefit agent
ATE273323T1 (de) 1999-12-28 2004-08-15 Esbatech Ag INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
ATE513854T1 (de) * 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
DE60139811D1 (de) 2000-12-19 2009-10-15 Unilever Nv Stabilisierung von schwerkettigen Kamelantikörpern durch Kaliumsalze
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
PT1419179E (pt) 2001-08-10 2010-03-16 Univ Aberdeen Domínios de ligação de antigenes
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP1318195A1 (en) * 2001-12-10 2003-06-11 CatchMabs B.V. A structure for presenting desired peptide sequences
AU2003205615B2 (en) 2002-01-10 2008-09-25 Universiteit Gent A novel splice variant of MyD88 and uses thereof
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
JP2006512891A (ja) * 2002-04-18 2006-04-20 ジェネンコー・インターナショナル・インク 糸状菌における機能性抗体の生産
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
US20060120999A1 (en) * 2002-09-16 2006-06-08 Dhar Arun K Protein and peptide expression for passive immunity
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1900753B1 (en) * 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US6974860B2 (en) * 2002-12-30 2005-12-13 Kimberly-Clark Worldwide, Inc. Target recognizing binding agents
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US20060234340A1 (en) * 2003-02-06 2006-10-19 Novozymes A/S Human heavy chain antibody expression in flamentous fungi
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
EP2128270B1 (en) 2003-08-08 2012-10-03 Genenews Inc. Osteoarthritis biomarkers and uses thereof
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
JP2008511286A (ja) 2004-06-02 2008-04-17 ダイアテック・ピーティワイ・リミテッド サメ類のＩｇＮＡＲドメインに基づく結合成分
EP1750759A4 (en) * 2004-06-04 2008-06-04 Genencor Int SCREENING PROCEDURE USING ANTIBODY HEAVY CHAINS
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
FR2879605B1 (fr) * 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
WO2006074947A2 (en) 2005-01-14 2006-07-20 Ablynx N.V. METHODS AND ASSAYS FOR DISTINGUISHING BETWEEN DIFFERENT FORMS OF DISEASES AND DISORDERS CHARACTERIZED BY THROMBOCYTOPENIA AND/OR BY SPONTANEOUS INTERACTION BETWEEN VON WILLEBRAND FACTOR (vWF) AND PLATELETS
CN103497993A (zh) 2005-02-07 2014-01-08 基因信息公司 轻度骨关节炎生物标志物及其用途
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
ES2626610T3 (es) 2005-08-30 2017-07-25 Intrexon Actobiotics Nv Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
US20080199460A1 (en) 2005-09-01 2008-08-21 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
TW200730825A (en) 2005-10-21 2007-08-16 Genenews Inc Method and apparatus for correlating levels of biomarker products with disease
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
US20100226920A1 (en) * 2006-03-27 2010-09-09 Ablynx N.V. Medical delivery device for therapeutic proteins based on single domain antibodies
TW200812616A (en) * 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US8874380B2 (en) 2010-12-09 2014-10-28 Rutgers, The State University Of New Jersey Method of overcoming therapeutic limitations of nonuniform distribution of radiopharmaceuticals and chemotherapy drugs
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
WO2008055924A1 (en) 2006-11-07 2008-05-15 Vib Vzw Diagnosis and treatment of t-cell acute lymphoblastic leukemia
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
AU2007333805B2 (en) 2006-12-18 2013-07-25 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
EP3118221B1 (en) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteins
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
RU2009137582A (ru) * 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
EP2599791A1 (en) 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
AU2008246442B2 (en) 2007-05-04 2014-07-03 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
MX376656B (es) 2007-05-14 2025-03-07 Kyowa Kirin Co Ltd Metodos para reducir niveles de basófilos.
CA2687896A1 (en) 2007-06-05 2008-12-18 Yale University Antibody directed against the d4 ig-like domain of the kit receptor
EP2164961B1 (en) * 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
BRPI0813645A2 (pt) * 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
AU2008270274B2 (en) 2007-07-03 2012-06-28 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
AU2008287128B2 (en) * 2007-08-10 2013-07-18 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
US8501907B2 (en) * 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
MX338397B (es) 2007-08-29 2016-04-15 Sanofi Aventis Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP2011500086A (ja) 2007-10-22 2011-01-06 シェーリング コーポレイション 完全ヒト抗ｖｅｇｆ抗体および使用方法
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
CN101977932B (zh) 2008-01-31 2014-09-03 美国政府健康及人类服务部 工程化抗体恒定结构域分子
GB2470328A (en) 2008-03-05 2010-11-17 Ablynx Nv Novel antigen binding dimer complexes, methods of making and uses thereof
GB0809069D0 (en) 2008-05-19 2008-06-25 Univ Leuven Kath Gene signatures
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
EP2316030B1 (en) 2008-07-25 2019-08-21 Wagner, Richard W. Protein screeing methods
NZ591488A (en) 2008-09-07 2012-11-30 Glyconex Inc Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
EP2379710A1 (en) 2008-12-19 2011-10-26 Schering Corporation Feed supplement for mammalian cell culture and methods of use
AU2010207552A1 (en) 2009-01-21 2011-09-01 Oxford Biotherapeutics Ltd. PTA089 protein
WO2010085590A1 (en) 2009-01-23 2010-07-29 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid gram positive bacteria
US20100189919A1 (en) 2009-01-27 2010-07-29 Xerox Corporation Imaging System And Process Using Monoclonal Antibodies
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
US10005830B2 (en) 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
CN102341412B (zh) 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 特异于cadm1 的全人抗体
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
EP2411413B1 (en) 2009-03-23 2016-05-11 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
US8609101B2 (en) 2009-04-23 2013-12-17 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
AU2010243551B2 (en) 2009-04-30 2015-03-26 Ablynx Nv Method for the production of domain antibodies
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
BR112012007875A2 (pt) 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
LT2805731T (lt) 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
JPWO2011046218A1 (ja) * 2009-10-16 2013-03-07 株式会社カネカ 抗体を生産するハンゼヌラ・ポリモルファ、それを用いた抗体の生産方法、およびそれにより得られる抗体
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
ES2784123T3 (es) 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
ES2724975T3 (es) * 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
DK2533761T3 (da) 2010-02-11 2019-06-24 Ablynx Nv Fremgangsmåder og sammensætninger til fremstilling af aerosoler
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
CN102242094A (zh) * 2010-05-14 2011-11-16 浙江大学 一种提高alpha半乳糖苷酶活力持续性的方法
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
AU2011273360A1 (en) 2010-07-02 2013-02-07 Vib Vzw The role of Fragile X mental retardation gene and protein in cancer metastasis
GB201012845D0 (en) 2010-07-30 2010-09-15 Vib Vzw Inhibition of dicer function for treatment of cancer
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
PT3556396T (pt) 2010-08-31 2022-07-04 Scripps Research Inst Anticorpos neutralizantes do vírus da imunodeficiência humana (vih)
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
GB201016864D0 (en) 2010-10-06 2010-11-17 Univ Aston Therapeutic methods
PL3279214T3 (pl) 2010-10-29 2025-03-24 Ablynx Nv Sposób wytwarzania pojedynczych domen zmiennych immunoglobuliny
ES2623912T3 (es) 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
EP2658869B1 (en) 2010-12-30 2019-06-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigen binding formats for use in therapeutic treatments or diagnostic assays
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
US9102969B2 (en) * 2011-03-11 2015-08-11 Kaneka Corporation Method for producing heterologous protein using yeast with disruption of VPS gene
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
AU2012234282B2 (en) 2011-03-28 2015-07-16 Ablynx Nv Method for producing solid formulations comprising immunoglobulin single variable domains
PT2691112T (pt) 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
WO2012152823A1 (en) 2011-05-09 2012-11-15 Ablynx Nv Method for the production of immunoglobulin single variable domains
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
CN103797029B (zh) 2011-05-17 2016-08-17 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
WO2012166906A1 (en) 2011-05-31 2012-12-06 Massachusetts Institute Of Technology Cell-directed synthesis of multifunctional nanopatterns and nanomaterials
EP2723772A1 (en) 2011-06-23 2014-04-30 Ablynx N.V. Immunoglobulin single variable domains directed against ige
PL2726508T3 (pl) 2011-06-28 2017-12-29 Oxford Biotherapeutics Ltd Przeciwciała przeciwko cyklazie ADP-rybozylowej 2
PL2726094T3 (pl) 2011-06-28 2017-06-30 Oxford Biotherapeutics Ltd Cel terapeutyczny i diagnostyczny
CN103747807B (zh) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97‑抗体缀合物和使用方法
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
WO2013025446A2 (en) 2011-08-12 2013-02-21 Omeros Corporation Anti-fzd10 monoclonal antibodies and methods for their use
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US20140235492A1 (en) 2011-09-20 2014-08-21 Institut National De La Sante Et De La Recherche Medicate (Inserm) Methods for preparing single domain antibody microarrays
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
US9575073B2 (en) 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
EP2785742B1 (en) 2011-11-02 2020-01-08 Apexigen, Inc. Anti-kdr antibodies and methods of use
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
CN104105709A (zh) 2011-12-05 2014-10-15 诺华股份有限公司 抗her3的结构域ii的表皮生长因子受体3(her3)抗体
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
JP2015509085A (ja) 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
WO2013109974A2 (en) 2012-01-20 2013-07-25 Genzyme Corporation Anti-cxcr3 antibodies
WO2013113696A1 (en) 2012-01-30 2013-08-08 Vib Vzw Means and method for diagnosis and treatment of alzheimer's disease
WO2013121042A1 (en) 2012-02-16 2013-08-22 Vib Vzw PP2A SUBUNITS IN DNA REPAIR, THE PP2A B55α SUBUNIT AS NOVEL PHD2 INTERACTING PROTEIN, AND IMPLICATIONS FOR CANCER
ES2693593T3 (es) 2012-03-15 2018-12-12 Omeros Corporation Composición y método para la diversificación de secuencias diana
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
JP6411333B2 (ja) 2012-05-24 2018-10-24 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 腫瘍関連マクロファージのターゲティングおよびｉｎｖｉｖｏイメージング用抗マクロファージマンノース受容体単一可変ドメイン
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CA3140358A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2904015A4 (en) 2012-10-02 2016-10-05 Univ Rutgers TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS
CN118955699A (zh) 2012-10-18 2024-11-15 洛克菲勒大学 广泛中和性抗hiv抗体
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
BR112015014621A2 (pt) 2012-12-21 2017-10-03 Amplimmune Inc Anticorpos anti-h7cr
CN105102478A (zh) 2013-01-30 2015-11-25 弗拉芒区生物技术研究所 用于筛选和药物发现目的的新型嵌合多肽
US20150368339A1 (en) 2013-02-05 2015-12-24 Vib Vzw Muscarinic acetylcholine receptor binding agents and uses thereof
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CA2902068C (en) 2013-02-28 2023-10-03 Caprion Proteomics Inc. Tuberculosis biomarkers and uses thereof
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP3611189A1 (en) 2013-03-14 2020-02-19 Novartis AG Antibodies against notch 3
NZ629682A (en) 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
JP6499090B2 (ja) 2013-03-15 2019-04-10 ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ 心血管疾患において使用するための抗マクロファージマンノース受容体単一可変ドメイン
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP2992101B1 (en) 2013-04-29 2018-10-10 Agrosavfe N.V. Agrochemical compositions comprising antibodies binding to sphingolipids
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
BR112015029395A2 (pt) 2013-05-24 2017-09-19 Medimmune Llc Anticorpos anti-b7-h5 e seus usos
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
SG11201509982UA (es) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
CA2919790C (en) 2013-08-02 2018-06-19 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
CN106029697B (zh) 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
US10233241B2 (en) 2014-01-30 2019-03-19 Vib Vzw Opioid receptor binding agents and uses thereof
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
HUE049514T2 (hu) 2014-04-25 2020-09-28 Bluebird Bio Inc Javított eljárások adoptív sejtterápiák kialakítására
PL3134432T3 (pl) 2014-04-25 2020-10-19 Bluebird Bio, Inc. Promotor mnd chimeryczne receptory antygenowe
AU2015252906C1 (en) 2014-05-01 2020-09-17 Bioasis Technologies Inc. p97-polynucleotide conjugates
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
CA2949109A1 (en) 2014-05-29 2015-12-03 Quark Pharmaceuticals, Inc. Methods and compositions for preventing ischemia reperfusion injury in organs
SI3151672T1 (sl) 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
DK3194976T3 (da) 2014-07-22 2020-07-13 Vib Vzw Fremgangsmåder til udvælgelse af midler, som stabiliserer proteinkomplekser
ES2878449T3 (es) 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
WO2016016329A1 (en) 2014-07-29 2016-02-04 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
EP3718574A1 (en) 2014-07-29 2020-10-07 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
EA035898B1 (ru) 2014-10-03 2020-08-28 НАНОТИКС, ЭлЭлСи Композиции и способы для ингибирования биологической активности растворимых биомолекул
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
US10858666B2 (en) 2014-11-05 2020-12-08 Biotalys Transgenic plants expressing a variable domain of a heavy chain antibody (VHH) that binds to a sphingolipid of a fungus
JP6800853B2 (ja) 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
HRP20191873T1 (hr) 2014-12-12 2020-01-24 Bluebird Bio, Inc. Kimerni antigenski receptori
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
MX391051B (es) 2014-12-30 2025-03-21 Celgene Corp Anticuerpos anti-cd47 y usos de los mismos.
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
KR20250005465A (ko) 2015-03-03 2025-01-09 키맵 리미티드 항체, 용도 및 방법
SG11201707538XA (en) 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
TR201904903T4 (tr) 2015-03-25 2019-05-21 Alexion Pharma Inc Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem.
WO2016151558A1 (en) 2015-03-25 2016-09-29 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
CA3255406A1 (en) 2015-03-31 2025-07-03 Sorriso Pharmaceuticals, Inc. Tnf-alpha binding polypeptides
SG11201706840WA (en) 2015-03-31 2017-09-28 Vhsquared Ltd Peptide construct having a protease-cleavable linker
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
CA2980087A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
EP3283108B1 (en) 2015-04-13 2020-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of haemorrhagic diseases
SG11201708804WA (en) 2015-05-07 2017-11-29 Agenus Inc Anti-ox40 antibodies and methods of use thereof
EP3736287A1 (en) 2015-05-11 2020-11-11 The Johns Hopkins University Autoimmune antibodies for use in inhibiting cancer cell growth
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
JP6432942B2 (ja) * 2015-06-23 2018-12-05 日立オートモティブシステムズ株式会社 ブレーキ装置
MX390949B (es) 2015-07-17 2025-03-21 Univ Brussel Vrije Fragmentos de anticuerpos radiomarcados para uso en tratamiento de cancer.
SI3331910T1 (sl) 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP4458417A3 (en) 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Novel anti-pd-1 antibodies
CN105063082A (zh) * 2015-09-07 2015-11-18 复旦大学 用于在马克思克鲁维酵母营养缺陷型菌株中进行外源基因分泌表达的重组载体
CN105132452A (zh) * 2015-09-07 2015-12-09 复旦大学 在马克斯克鲁维酵母营养缺陷型菌株中表达融合了组氨酸标签的外源基因的重组载体
WO2017040529A1 (en) 2015-08-31 2017-03-09 Bluebird Bio, Inc. Anti-sialyl tn chimeric antigen receptors
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
JP6955487B2 (ja) 2015-09-24 2021-10-27 アブビトロ， エルエルシー Ｈｉｖ抗体組成物および使用方法
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
EP3858993A1 (en) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
KR20180080337A (ko) 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
US11045547B2 (en) 2015-12-16 2021-06-29 Merck Sharp & Dohme Corp. Anti-LAG3 antibodies and antigen-binding fragments
CA3005696A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EP3433615A1 (en) 2016-03-21 2019-01-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for diagnosis and treatment of solar lentigo
CA3007135A1 (en) 2016-03-23 2017-09-28 Mabspace Biosciences (Suzhou) Co., Ltd Novel anti-pd-l1 antibodies
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ， インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2017176762A1 (en) 2016-04-06 2017-10-12 Nanotics, Llc Particles comprising subparticles or nucleic acid scaffolds
EP3443002A4 (en) 2016-04-14 2019-12-04 Bluebird Bio, Inc. SYSTEMS FOR RECOVERED CHIMERIC ANTIGEN RECEPTORS
CA3019588A1 (en) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
US11243214B2 (en) 2016-04-22 2022-02-08 Université Libre de Bruxelles Biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
WO2017182605A1 (en) 2016-04-22 2017-10-26 Université Libre de Bruxelles A new biomarker expressed in pancreatic beta cells useful in imaging or targeting beta cells
CN109311968A (zh) 2016-05-02 2019-02-05 埃博灵克斯股份有限公司 治疗rsv感染
EP3464360B1 (en) 2016-05-27 2025-11-12 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
US12084495B2 (en) 2016-08-03 2024-09-10 Nextcure, Inc. Compositions and methods for modulating LAIR signal transduction
TWI765900B (zh) 2016-08-03 2022-06-01 中國大陸商軒竹（北京）醫藥科技有限公司 哌唑黴素(plazomicin)抗體及使用方法
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
KR20190049866A (ko) 2016-09-20 2019-05-09 우시 바이올로직스 아일랜드 리미티드 신규한 항-ｐｃｓｋ９ 항체
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
EP3519438A1 (en) 2016-09-30 2019-08-07 VHsquared Limited Compositions
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
WO2018071624A1 (en) 2016-10-12 2018-04-19 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
EP3529619B1 (en) 2016-10-19 2021-06-30 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5a in a sample
WO2018075758A1 (en) 2016-10-19 2018-04-26 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
US20200057046A1 (en) 2016-10-27 2020-02-20 Alexion Pharmaceuticals, Inc. Assay for c5b-9 deposition in complement-associated disorders
CN110352073A (zh) 2016-10-28 2019-10-18 机敏医药股份有限公司 针对timp-2的抗体用于改善肾功能的用途
WO2018078083A1 (en) 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
JP7267914B2 (ja) 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018085690A1 (en) 2016-11-04 2018-05-11 Bluebird Bio, Inc. Anti-bcma car t cell compositions
JP7045724B2 (ja) 2016-11-07 2022-04-01 ニューラクル サイエンス カンパニー リミテッド 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
MA46862A (fr) 2016-11-17 2019-09-25 Bluebird Bio Inc Convertisseur de signaux tgf béta
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
DK3551660T5 (da) 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
WO2018141753A1 (en) 2017-01-31 2018-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating squamous cell carcinomas
JP7186401B2 (ja) 2017-02-28 2022-12-09 フエー・イー・ベー・フエー・ゼツト・ウエー タンパク質の経口送達のための手段及び方法
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
KR102746901B1 (ko) 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
CN110753702B (zh) 2017-03-15 2022-09-20 清华大学 抗trkb抗体
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018183182A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
US20200033347A1 (en) 2017-04-18 2020-01-30 Universite Libre De Bruxelles Biomarkers And Targets For Proliferative Diseases
EP3612561A1 (en) 2017-04-19 2020-02-26 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
CN110506056A (zh) 2017-04-21 2019-11-26 斯塔滕生物技术有限公司 抗apoc3抗体和其使用方法
SG11201909395TA (en) 2017-04-27 2019-11-28 Tesaro Inc Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
KR20200005635A (ko) 2017-05-11 2020-01-15 브이아이비 브이지더블유 가변 면역글로불린 도메인의 글리코실화
WO2018208553A1 (en) 2017-05-12 2018-11-15 Augusta University Research Institute, Inc. Human alpha fetoprotein-specific t cell receptors and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
NZ759601A (en) 2017-06-02 2023-06-30 Merck Patent Gmbh Aggrecan binding immunoglobulins
TW202417517A (zh) 2017-06-02 2024-05-01 德商麥克專利有限公司 與ｍｍｐ１３結合之免疫球蛋白
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
CN118894939A (zh) 2017-06-02 2024-11-05 默克专利股份有限公司 结合adamts的免疫球蛋白
EP3415010A1 (en) 2017-06-13 2018-12-19 Agrosavfe Nv Insect-controlling polypeptides and methods
BR112019027729A2 (pt) 2017-06-27 2020-08-18 Neuracle Science Co., Ltd anticorpos anti-fam19a5 e seus usos
JP2020526584A (ja) 2017-06-28 2020-08-31 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用
AU2018301393B2 (en) 2017-07-11 2025-02-27 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and uses thereof
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
CA3070253A1 (en) 2017-07-19 2019-01-24 Vib Vzw Serum albumin binding agents
EP3684811A2 (en) 2017-08-17 2020-07-29 Massachusetts Institute of Technology Multiple specificity binders of cxc chemokines and uses thereof
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
MX2020002612A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Anticuerpos de la proteina de muerte celular programada 1.
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
KR20200091400A (ko) 2017-10-31 2020-07-30 브이아이비 브이지더블유 신규한 항원-결합 키메라 단백질 및 이의 방법 및 용도
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
PE20210119A1 (es) 2017-10-31 2021-01-19 Staten Biotechnology B V Anticuerpos anti-apoc3 y metodos de uso de estos
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
CN112236514A (zh) 2017-12-05 2021-01-15 塞利亚德股份公司 改善细胞过继转移的持久性的组合物和方法
JP7807196B2 (ja) 2017-12-05 2026-01-27 セリアド オンコロジー エス．アー． Ｎｋｇ２ｄベースの受容体を発現する免疫細胞のフラトリサイドの減少
US11946094B2 (en) 2017-12-10 2024-04-02 Augusta University Research Institute, Inc. Combination therapies and methods of use thereof
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
CN117924477A (zh) 2017-12-19 2024-04-26 洛克菲勒大学 具有改进的效应子功能的人IgG Fc结构域变体
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
CN108218990B (zh) 2017-12-29 2021-03-02 南京优迈生物科技有限公司 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
EP3740231A4 (en) 2018-01-18 2022-03-23 California Institute of Technology PROGRAMMABLE PROTEIN CIRCUITS IN LIVING CELLS
CN112566934B (zh) 2018-01-23 2024-09-17 奈斯科尔公司 B7-h4抗体及其使用方法
AU2019215202B2 (en) 2018-02-01 2025-11-13 Memorial Sloan Kettering Cancer Center Antibodies to Galectin-3 and methods of use thereof
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019157191A1 (en) 2018-02-07 2019-08-15 Georgia Tech Research Corporation Methods for multiplexed cell isolation using dna gates
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
CA3092421A1 (en) 2018-03-01 2019-09-06 Vrije Universiteit Brussel Human pd-l1-binding immunoglobulins
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US12202894B2 (en) 2018-03-20 2025-01-21 WuXi Biologics Ireland Limited Anti-TIM-3 antibodies
US11661452B2 (en) 2018-03-20 2023-05-30 WuXi Biologics Ireland Limited Anti-lag-3 antibody polypeptide
CN112512571B (zh) 2018-03-22 2025-02-07 表面肿瘤学有限责任公司 抗il-27抗体及其用途
IL277307B2 (en) 2018-03-23 2025-03-01 Univ Bruxelles Wnt signaling agonist molecules
CA3095080A1 (en) 2018-03-27 2019-10-03 Coen MAAS Targeted thrombolysis for treatment of microvascular thrombosis
US20210047696A1 (en) 2018-03-28 2021-02-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2019200357A1 (en) 2018-04-12 2019-10-17 Surface Oncology, Inc. Biomarker for cd47 targeting therapeutics and uses therefor
WO2019197683A1 (en) 2018-04-13 2019-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019217913A1 (en) 2018-05-10 2019-11-14 Sensei Biotherapeutics, Inc. Aspartate beta-hydroxylase chimeric antigen receptors and uses thereof
AU2019265888B2 (en) 2018-05-10 2026-04-09 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
DK3806903T5 (da) 2018-06-14 2024-08-19 2Seventy Bio Inc Cd79a kimæriske antigenreceptorer
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
US20210292422A1 (en) 2018-07-05 2021-09-23 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
TW202019474A (zh) 2018-07-11 2020-06-01 美商西建公司 抗bcma嵌合抗原受體之用途
WO2020016160A1 (en) 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
US12485126B2 (en) 2018-07-19 2025-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
EP3813867A1 (en) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Treatment of lymmphatic metastases
US20210186880A1 (en) 2018-08-03 2021-06-24 Brown University Oral formulations with increased uptake
WO2020033923A1 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antigen binding agents that bind cd277 and uses thereof
WO2020033925A2 (en) 2018-08-09 2020-02-13 Compass Therapeutics Llc Antibodies that bind cd277 and uses thereof
EP3833442A2 (en) 2018-08-09 2021-06-16 Compass Therapeutics LLC Antibodies that bind cd277 and uses thereof
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
US11542305B2 (en) 2018-08-31 2023-01-03 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
JP7404343B2 (ja) 2018-09-04 2023-12-25 ナンジン ユーマブ－バイオファーマ カンパニー リミテッド 融合タンパク質、並びに腫瘍及び／又はウイルス感染の治療薬を製造するためのその使用
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
AU2019338454A1 (en) 2018-09-14 2021-04-08 The Rockefeller University Anti-HIV antibody 10-1074 variants
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
KR20210070300A (ko) 2018-10-03 2021-06-14 스태튼 바이오테크놀로지 비.브이. 사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020084056A1 (en) 2018-10-25 2020-04-30 Swiss Pharma International Ag Anti-human cd89 antibodies and uses thereof
US20220000893A1 (en) 2018-10-31 2022-01-06 |Nserm (Institut National De La Santé Et De La Recherche Médicale) Method for treating t-helper type 2 mediated disease
CA3118692A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
US12422441B2 (en) 2018-12-07 2025-09-23 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
EP3894440A4 (en) 2018-12-13 2022-09-07 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN113195533B (zh) 2019-01-02 2024-04-26 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
WO2020146627A1 (en) 2019-01-10 2020-07-16 California Institute Of Technology A synthetic system for tunable thresholding of protein signals
JP2022522265A (ja) 2019-01-16 2022-04-15 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル エリスロフェロンの変異体及びその使用
BR112021013571A2 (pt) 2019-01-16 2021-09-21 Compass Therapeutics Llc Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
MX2021010003A (es) 2019-02-26 2021-12-10 Inspirna Inc Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
PH12021551720A1 (en) 2019-03-01 2022-03-28 Allogene Therapeutics Inc Dll3 targeting chimeric antigen receptors and binding agents
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2020205827A1 (en) 2019-04-01 2020-10-08 Rush University Medical Center Reagents and assays using modified integrin domains
WO2020208082A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
WO2020221769A1 (en) 2019-04-29 2020-11-05 Confo Therapeutics N.V. Screening methods and assays for use with transmembrane proteins, in particular with gpcrs
EP3962599A1 (en) 2019-04-30 2022-03-09 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
EP3962497A4 (en) 2019-04-30 2023-01-18 Myeloid Therapeutics, Inc. GENETICALLY ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
WO2020229546A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
US20220227859A1 (en) 2019-05-16 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat type 2 inflammation or mast-cell dependent disease
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020239945A1 (en) 2019-05-28 2020-12-03 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
AU2020289301B2 (en) 2019-06-04 2025-07-24 Biotheus Inc. CEACAM5-resistant monoclonal antibody and preparation method thereof and use thereof
US12559552B2 (en) 2019-06-21 2026-02-24 Sorriso Pharmaceuticals, Inc. IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
KR20220063148A (ko) 2019-06-21 2022-05-17 소리소 파마슈티컬스 인크. 조성물
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
CA3145345A1 (en) 2019-07-15 2021-01-21 Intervet International B.V. Caninized antibodies against canine ctla-4
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
EP4025712A1 (en) 2019-09-05 2022-07-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Method of treatment and pronostic of acute myeloid leukemia
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
MX2022003719A (es) 2019-09-25 2022-04-26 Surface Oncology Inc Anticuerpos anti-il-27 y sus usos.
TW202126295A (zh) 2019-09-27 2021-07-16 大陸商江蘇挪貝肽醫藥科技有限公司 一種治療心境障礙的方法
WO2021058744A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
WO2021078786A1 (en) 2019-10-21 2021-04-29 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
WO2021086948A1 (en) 2019-10-28 2021-05-06 Georgia Tech Research Corporation Mrna-encoded antibodies for contraception
WO2021086953A1 (en) 2019-10-28 2021-05-06 Georgia Tech Research Corporation Compositions and methods for prophylaxis of hiv
WO2021091978A1 (en) 2019-11-05 2021-05-14 Celgene Corporation Uses of anti-bcma chimeric antigen receptors
CA3160506A1 (en) 2019-11-11 2021-05-20 Ibi-Ag Innovative Bio Insecticides Ltd. Insect control nanobodies and uses thereof
US20220411495A1 (en) 2019-11-27 2022-12-29 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
WO2021105384A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
WO2021105391A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination comprising nupr1 inhibitors to treat cancer
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
WO2021127500A1 (en) 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
KR20220128363A (ko) 2019-12-24 2022-09-20 제이제이피 바이오로직스 에스피. 제트 오.오. 항-인간 hvem(tnfrsf14) 항체 및 그의 용도
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3160204A1 (en) 2020-01-06 2021-07-15 Vaccinex, Inc. Anti-ccr8 antibodies and uses thereof
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
CA3168729A1 (en) 2020-02-24 2021-09-02 Melinda MATA Methods for expanding t cells for the treatment of cancer and related malignancies
KR20230012464A (ko) 2020-02-25 2023-01-26 브이아이비 브이지더블유 류신-풍부 반복 키나제 2 알로스테릭 조절제
JP2023517063A (ja) 2020-03-10 2023-04-21 マサチューセッツ インスティテュート オブ テクノロジー 操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物
BR112022017924A2 (pt) 2020-03-10 2022-12-20 Massachusetts Inst Technology Composições e métodos para imunoterapia de câncer npm1c-positivo
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
AU2021236302A1 (en) 2020-03-12 2022-10-20 Immune-Onc Therapeutics, Inc. Novel anti-LILRB4 antibodies and derivative products
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
CN115397868A (zh) 2020-03-30 2022-11-25 埃博灵克斯股份有限公司 用于产生和纯化多价免疫球蛋白单可变域的方法
WO2021198396A1 (en) 2020-03-31 2021-10-07 Biotalys NV Anti-fungal polypeptides
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
EP4135837A1 (en) 2020-04-16 2023-02-22 Assistance Publique, Hopitaux De Paris Methods for treating a complement mediated disorder caused by viruses
KR20230004739A (ko) 2020-04-21 2023-01-06 제이제이피 바이오로직스 에스피. 제트 오.오. 인간화 항-인간 cd89 항체 및 이의 용도
CN113527488B (zh) 2020-04-22 2026-04-17 迈威(上海)生物科技股份有限公司 一种靶向人程序性死亡配体1（pd-l1）的单可变域抗体及其衍生物
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
EP4153192B8 (en) 2020-05-19 2024-09-04 Institut Curie Antagonist of cd44/hyaluronic acid pathway for use in a method for the treatment of cytokine release syndrome
MX2022015157A (es) 2020-06-02 2023-01-16 Arcus Biosciences Inc Anticuerpos para tigit.
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
WO2021255204A1 (en) 2020-06-18 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
WO2022023584A1 (en) 2020-07-31 2022-02-03 Biotalys NV Methods of increasing recombinant protein yields
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2022063947A1 (en) 2020-09-24 2022-03-31 Vib Vzw Combination of p2y6 inhibitors and immune checkpoint inhibitors
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
AU2021350156A1 (en) 2020-09-25 2023-06-08 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4232064A1 (en) 2020-10-21 2023-08-30 Institut National de la Santé et de la Recherche Médicale (INSERM) C-terminal sparc fragments for treating cancer
EP4241278A2 (en) 2020-11-04 2023-09-13 Celgene Corporation Car t cell therapy in patients who have had prior anti-cancer alkylator therapy
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
EP4272002A1 (en) 2020-12-04 2023-11-08 Celgene Corporation Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
EP4263602A1 (en) 2020-12-18 2023-10-25 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
WO2022136647A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Human ccr8 binders
EP4267621A1 (en) 2020-12-24 2023-11-01 Vib Vzw Murine cross-reactive human ccr8 binders
WO2022161502A1 (zh) 2021-02-01 2022-08-04 羿尊生物医药（浙江）有限公司 一种靶向蛋白降解系统及其应用
IL304929A (en) 2021-02-05 2023-10-01 Vib Vzw [Be/Be Sarbevirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
US20240229154A9 (en) 2021-02-12 2024-07-11 Institut National de la Santé et de la Recherche Médicale Method for prognosis and treating a patient suffering from cancer
WO2022175392A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
EP4294516A1 (en) 2021-02-19 2023-12-27 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
EP4322938A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve nk cells cytotoxicity
EP4322937A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve the anti-tumoral activity of macrophages
JP2024517413A (ja) 2021-04-16 2024-04-22 セルジーン コーポレーション 以前に幹細胞移植を受けた患者におけるｔ細胞療法
WO2022236134A1 (en) 2021-05-07 2022-11-10 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica
US20240261446A1 (en) 2021-05-17 2024-08-08 Université de Liège Anti-cd38 single domain antibodies in disease monitoring and treatment
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
WO2022253910A1 (en) 2021-06-02 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) A new method to treat an inflammatory skin disease
US20250019446A1 (en) 2021-06-16 2025-01-16 Shanghai Sinobay Biotechnology Co., Ltd. Antibody Targeting Axl Protein and Antigen Binding Fragment Thereof, and Preparation Method Therefor and Application Thereof
WO2022268993A1 (en) 2021-06-23 2022-12-29 Vib Vzw Means and methods for selection of specific binders
WO2023274183A1 (zh) 2021-06-29 2023-01-05 江苏先声药业有限公司 Cd16抗体及其应用
US20240343803A1 (en) 2021-07-30 2024-10-17 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
EP4377352A2 (en) 2021-07-30 2024-06-05 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
JP2024530943A (ja) 2021-08-06 2024-08-27 アンスティテュ・レジオナル・デュ・カンセール・ドゥ・モンペリエ がんの処置のための方法
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
US20240316061A1 (en) 2021-09-17 2024-09-26 Institut Curie Bet inhibitors for treating pab1 deficient cancer
US20250134952A1 (en) 2021-09-20 2025-05-01 Institut National de la Santé et de la Recherche Médicale Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
US20240401146A1 (en) 2021-10-06 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
WO2023057601A1 (en) 2021-10-06 2023-04-13 Biotalys NV Anti-fungal polypeptides
AU2022364888A1 (en) 2021-10-14 2024-05-30 Latticon (Suzhou) Biopharmaceuticals Co., Ltd. Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
WO2023073099A1 (en) 2021-10-28 2023-05-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2023078906A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating acute myeloid leukemia
EP4180518A1 (en) 2021-11-12 2023-05-17 Istituto Europeo di Oncologia S.r.l. T cells and uses thereof
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
WO2023098846A1 (zh) 2021-12-03 2023-06-08 江苏先声药业有限公司 抗bcma纳米抗体及其应用
IL313473A (en) 2021-12-15 2024-08-01 Interius Biotherapeutics Inc Pseudotyped viral particles, compositions comprising the same, and uses thereof
KR20240122867A (ko) 2021-12-17 2024-08-13 아블린쓰 TCRαβ, CD33, 및 CD123을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
WO2023125888A1 (zh) 2021-12-31 2023-07-06 山东先声生物制药有限公司 一种gprc5d抗体及其应用
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
KR20240137086A (ko) 2022-01-28 2024-09-19 조지아뮨 인코포레이티드 Pd-1 작용제인 세포예정사 단백질 1에 대한 항체
EP4473108A1 (en) 2022-02-02 2024-12-11 Biotalys NV Methods for genome editing
EP4476250A1 (en) 2022-02-07 2024-12-18 Vib Vzw Engineered stabilizing aglycosylated fc-regions
EP4476355A1 (en) 2022-02-11 2024-12-18 Henkel AG & Co. KGaA Process for the synthesis of alpha-methylene-gamma-butyrolactone
WO2023164487A1 (en) 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
WO2023183474A1 (en) 2022-03-23 2023-09-28 Bodhi Bio Llc Antigen-specific therapy for autoimmune diseases
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023213751A1 (en) 2022-05-02 2023-11-09 Umc Utrecht Holding B.V Single domain antibodies for the detection of plasmin-cleaved vwf
AU2023264591A1 (en) 2022-05-02 2024-11-07 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same
CN119213034A (zh) 2022-05-17 2024-12-27 苏州创胜医药集团有限公司 双功能蛋白质及其制剂和用途
CA3249283A1 (en) 2022-05-18 2023-11-23 Vib Vzw BINDERS OF SARBECOVIRUS SPICULE S2 SUBUNITS
WO2023224715A1 (en) 2022-05-19 2023-11-23 Massachusetts Institute Of Technology Car cells targeting an inserted ligand
US20240025987A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20240026001A1 (en) 2022-05-25 2024-01-25 Surface Oncology, Inc. Use of anti-il-27 antibodies
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
IL317463A (en) 2022-06-06 2025-02-01 Shandong Simcere Biopharmaceutical Co Ltd Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application
KR20250035053A (ko) 2022-06-07 2025-03-11 리제너론 파아마슈티컬스, 인크. T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
US20240117038A1 (en) 2022-07-18 2024-04-11 Ablynx N.V. Cx3cr1-binding compounds, methods and uses thereof
KR20250057777A (ko) 2022-07-25 2025-04-29 인테리우스 바이오테라퓨틱스, 인코포레이티드 돌연변이된 폴리펩티드, 이를 포함하는 조성물, 및 그 용도(mutated polypeptides, compositions comprising the same, and uses thereof)
WO2024028476A1 (en) 2022-08-05 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en) 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
EP4583911A1 (en) 2022-09-06 2025-07-16 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
WO2024228717A2 (en) 2022-09-07 2024-11-07 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
EP4594348A1 (en) 2022-09-27 2025-08-06 Vib Vzw Antivirals against human parainfluenza virus
EP4619156A1 (en) 2022-11-15 2025-09-24 Imec VZW Method and system for droplet manipulation
WO2024112734A1 (en) 2022-11-21 2024-05-30 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof
TW202440623A (zh) 2022-11-28 2024-10-16 美商艾洛基因醫療公司 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
WO2024126805A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
WO2024133723A1 (en) 2022-12-22 2024-06-27 Institut National de la Santé et de la Recherche Médicale Methods for decreasing therapeutic acquired resistance to chemotherapy and/or radiotherapy
EP4638735A1 (en) 2022-12-22 2025-10-29 Biotalys NV Methods for genome editing
WO2024131956A1 (zh) 2022-12-23 2024-06-27 成都恩沐生物科技有限公司 靶向gprc5d的多特异性多肽复合物
US20260026500A1 (en) 2022-12-29 2026-01-29 Biotalys NV Agrochemical compositions
EP4643878A2 (en) 2022-12-29 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Pharmaceutical preparation comprising therapeutic antibody and use thereof
EP4642232A1 (en) 2022-12-30 2025-11-05 Biotalys NV Self-emulsifiable concentrate
WO2024141641A2 (en) 2022-12-30 2024-07-04 Biotalys NV Secretion signals
WO2024141645A1 (en) 2022-12-30 2024-07-04 Biotalys N.V. Agglomerate
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
EP4655324A1 (en) 2023-01-27 2025-12-03 Vib Vzw Cd163-binding conjugates
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024165710A1 (en) 2023-02-09 2024-08-15 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
TW202436345A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗ｃｄ３多特異性抗體及使用方法
WO2024184810A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184812A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cldn6 antibodies and methods of use
EP4677083A1 (en) 2023-03-07 2026-01-14 Institut Curie Ung/udg inhibition in brca-associated cancer
EP4676453A1 (en) 2023-03-08 2026-01-14 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of food allergy
EP4680624A1 (en) 2023-03-14 2026-01-21 Aarhus Universitet Genetically altered nfr5 receptor kinases
EP4683630A1 (en) 2023-03-21 2026-01-28 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
AU2024240821A1 (en) 2023-03-23 2025-11-06 Bodhi Bio Llc Compositions and methods for antigen-specific therapy
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
EP4695290A1 (en) 2023-04-13 2026-02-18 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024226829A2 (en) 2023-04-26 2024-10-31 Yale University Enpp3-binding molecules, compositions formed therefrom, and methods of use thereof for the treatment of cancer
EP4709753A1 (en) 2023-05-11 2026-03-18 Vib Vzw Slc4a4/nbce1 inhibitors
CN121604979A (zh) 2023-05-23 2026-03-03 上海联进生物科技有限公司 包含效应分子的pd-l1和trop-2靶向缀合物及其用途
EP4727570A1 (en) 2023-06-13 2026-04-22 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024259299A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Compositions and methods for identification of vhh antibodies that bind a target antigen
WO2024259305A1 (en) 2023-06-14 2024-12-19 The Broad Institute, Inc. Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
AU2024287547A1 (en) 2023-07-07 2026-01-22 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2025032112A1 (en) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of type 2-mediated diseases
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078851A1 (en) 2023-10-11 2025-04-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of treating cognitive deficit
NL2036011B1 (en) 2023-10-12 2025-04-30 Synapse Res Institute Molecules for reversing anti-coagulant activity of direct oral anticoagulants
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
US12378306B2 (en) 2023-12-22 2025-08-05 Biotalys NV Anti-fungal VHH antibodies
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025162980A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of breast cancer using a jnk-1 inhibitor
WO2025168716A1 (en) 2024-02-07 2025-08-14 Eyebiotech Limited Compositions, doses, and methods for treatment of ocular diseases
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
WO2025179282A1 (en) 2024-02-23 2025-08-28 Flatiron Bio, Llc Antibodies targeting epstein-barr virus proteins and methods of use
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025191018A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025212726A2 (en) 2024-04-04 2025-10-09 Compass Therapeutics, Inc. Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
WO2025226603A1 (en) 2024-04-22 2025-10-30 Surface Oncology, LLC Methods for treating cancer using anti-ccr8 antibodies
WO2025224050A1 (en) 2024-04-22 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of patients suffering from hypomelanosis of ito
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025238157A1 (en) 2024-05-15 2025-11-20 Katholieke Universiteit Leuven Multispecific binding agent suitable for use in cancer immune therapy
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026002934A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Combination of a slc16a1 inhibitor and a smad3 inhibitor for treating cancer
WO2026003239A2 (en) 2024-06-28 2026-01-02 Institut National de la Santé et de la Recherche Médicale Method to improve macrophages functions
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026008785A1 (en) 2024-07-03 2026-01-08 Biotalys NV Agrochemical compositions
WO2026013153A1 (en) 2024-07-10 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from myc-high tumors
WO2026027659A1 (en) 2024-07-31 2026-02-05 Seni-Preps B.V. Improved immunoglobulin single variable domains that inhibit urease and use thereof
WO2026037841A1 (en) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Anti-fgfr4 molecules and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026053130A1 (en) 2024-09-03 2026-03-12 Mirobio Limited Anti-btla antibodies and uses of the same
WO2026055167A1 (en) 2024-09-05 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and use of biomarkers in uses thereof
WO2026055168A1 (en) 2024-09-06 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and uses and doses thereof
WO2026052851A2 (en) 2024-09-09 2026-03-12 Institut National de la Santé et de la Recherche Médicale Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
WO2026060159A1 (en) 2024-09-13 2026-03-19 Gilead Sciences, Inc. Vhhs against hsv and uses of the same
WO2026068859A1 (en) 2024-09-30 2026-04-02 Université Libre de Bruxelles Wnt signaling agonist molecules in the treatment of a bone-related disease or disorder
WO2026076388A1 (en) 2024-10-03 2026-04-09 The Broad Institute, Inc. Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL82935A0 (en) * 1986-08-12 1987-12-20 Phillips Petroleum Co Secretion of heterologous proteins from yeast
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
GB8927230D0 (en) 1989-12-01 1990-01-31 Unilever Plc Reagents
FI913434A7 (fi) 1990-07-16 1992-01-17 Technical Research Centre F Finland Rekombinanta fusionsproteiner vilka utsoendras.
DK1621554T4 (da) * 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
EP0584421A1 (en) 1992-08-21 1994-03-02 Cécile Casterman Immunoglobulins devoid of light chains
HU219674B (hu) * 1992-08-28 2001-06-28 Novo Nordisk A/S Glukagon-receptort kódoló DNS-molekulák, glukagon-receptor peptidek, glukagon-receptort blokkoló monoklonális ellenanyagok, és eljárások előállításukra

Also Published As

Publication number Publication date
ATE204325T1 (de) 2001-09-15
US20050130266A1 (en) 2005-06-16
DK0698097T3 (da) 2001-10-08
DE69427974T2 (de) 2001-12-06
WO1994025591A1 (en) 1994-11-10
DE69427974D1 (de) 2001-09-20
US7794981B2 (en) 2010-09-14
US6838254B1 (en) 2005-01-04
AU6796094A (en) 1994-11-21

Similar Documents

Publication Publication Date Title
ES2162863T3 (es) Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
DK1107989T3 (da) Ekspression og eksport af angiostatin og endostatin som immunfusiner
AR077088A1 (es) Proteinas biespecificas de union a antigeno
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
ES2161751T3 (es) Anticuerpo monoclonal que se une especificamente al endotelio vascular tumoral y usos del mismo.
FI104047B1 (fi) DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
CO5050255A1 (es) Anticuerpo especifico de fap con productividad mejorada
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
PT994903E (pt) Metodos e composicoes para glicoproteinas galactosiladas
DK0894126T3 (da) Alkalisk phosphatase-deficient trådformet svamp
AR021296A1 (es) Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden
DE69133179D1 (de) Katalytische antikörperkomponente
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
ES2061736T3 (es) Anticuerpos monoclonales contra interleucina-4 humana e hibridomas que los producen.
DE59010826D1 (de) Monoklonale Antikörper (MAK) gegen tumorassoziierte Antigene, ihre Herstellung und Verwendung
DE59309458D1 (de) Synthetische Peptide, Antikörper dagegen und ihre Verwendung
PE20232050A1 (es) Anticuerpos anti-cd19 y estructuras car-t
MX2022003074A (es) Anticuerpos anti-cd371, y usos de los mismos.
BR0015287A (pt) Moléculas recombinantes de fusão
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
DE69934250D1 (de) Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
ATE141415T1 (de) Konjugate von antikörpern mit variablen domänen
MX2022009138A (es) Anticuerpos y fragmentos de anticuerpos anti-her2 condicionalmente activos, sus inmunoconjugados y usos de estos.
MX2025000311A (es) Constructos de union a antigeno dll3

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 698097

Country of ref document: ES